World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
143
Citations
111118
World Ranking
147
National Ranking
2

Medicine

D-Index
143
Citations
113600
World Ranking
1468
National Ranking
44

David A. Cooper publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David A. Cooper sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 902 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David A. Cooper D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David A. Cooper sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 143 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

David A. Cooper was affiliated with the University of New South Wales in Australia. Their primary field of study was Medicine, with a focus on subfields including Infectious Diseases, Epidemiology, Animal Science and Zoology, Cardiology and Cardiovascular Medicine, and Health.

The main topics covered in their research included:

  • SARS-CoV-2 and COVID-19 Research
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing
  • Animal Virus Infections Studies
  • Influenza Virus Research Studies

David A. Cooper contributed articles to several frequent publication venues, including:

  • New England Journal of Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Open Forum Infectious Diseases
  • Nature
  • The Journal of Infectious Diseases

Some of the recent papers associated with their research included:

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, 2020, New England Journal of Medicine
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, 2020, New England Journal of Medicine
  • COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, 2020, Nature
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, Nature
  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents, 2021, New England Journal of Medicine

Frequent coauthors included:

  • Kena A. Swanson
  • Alejandra Gurtman
  • Uğur Şahin
  • William C. Gruber
  • Philip R. Dormitzer

Best Publications

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

    Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • CD4+ count-guided interruption of antiretroviral treatment.

    Wafaa El-Sadr;Wafaa El-Sadr;Jens D Lundgren;James Neaton;Fred Gordin

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection

    Sean Emery;Shweta Sharma;Gerd Fätkenheuer;Josep M. Llibre

  • A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

    Andrew Carr;Katherine Samaras;Samantha Burton;Matthew Law

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

    Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

  • Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

    Andrew Carr;Katherine Samaras;Anna Thorisdottir;Gilbert R Kaufmann

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • Adverse effects of antiretroviral therapy

    Andrew Carr;David A Cooper;David A Cooper

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

    Andrew Carr;Katherine Samaras;Donald J Chisholm;David A Cooper

  • Acute AIDS Retrovirus Infection. Definition of a Clinical Illness Associated With Seroconversion

    DavidA. Cooper;DavidA. Cooper;DavidA. Cooper;Prudence Maclean;Prudence Maclean;Prudence Maclean;Robert Finlayson;Robert Finlayson;Robert Finlayson;HarryM. Michelmore;HarryM. Michelmore;HarryM. Michelmore

  • A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

    Julio S. G. Montaner;Peter Reiss;David Cooper;Stefano Vella

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

    Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

    Andrew Carr;John Miller;Matthew Law;David A. Cooper

  • BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

    Ugur Sahin;Alexander Muik;Isabel Vogler;Evelyna Derhovanessian

Frequent Co-Authors

Anthony D. Kelleher
Anthony D. Kelleher University of New South Wales
Andrew Carr
Andrew Carr University of Oxford
Sean Emery
Sean Emery University of New South Wales
Matthew Law
Matthew Law University of New South Wales
John Zaunders
John Zaunders Ascension Health
Ronald Penny
Ronald Penny University of New South Wales
John M. Kaldor
John M. Kaldor University of New South Wales
Kiat Ruxrungtham
Kiat Ruxrungtham Chulalongkorn University
Janaki Amin
Janaki Amin Macquarie University
Joep M. A. Lange
Joep M. A. Lange University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Immunology in the USA opens doors to diverse healthcare careers, especially in nursing specialties focused on immune-related disorders. Many students consider pursuing an easy nurse practitioner programs to get into as a practical entry point, balancing accessibility with quality education. These programs can provide foundational clinical skills applicable to immunology-related fields.

For those interested in mental health and immune system connections, the best online psychiatric mental health nurse practitioner programs offer specialized training alongside strong clinical placement opportunities. This pathway is excellent for students seeking hands-on experience while studying remotely.

Budget-friendly options are also available. Students looking for cost-effective education might explore the cheapest online pmhnp programs, which provide reputable credentials without the financial burden.

Career prospects post-degree are promising, with many graduates advancing to earn a Doctor of Nursing Practice (DNP). Understanding the doctor of nursing practice salary by state can help students make informed decisions about where to study and work within the USA.

Best Scientists Citing David A. Cooper

Recently Published Articles